Peptides Antimicrobial Market 2026: $6.8B Growth Driven by 14.2% CAGR, Superbug Resistance & Novel Therapeutics
Abstract: The antimicrobial peptide (AMP) market is projected to reach $6.8 billion by 2026, growing at a 14.2% CAGR, driven by superbug resistance and novel therapeutics. AMPs offer advantages over traditional antibiotics, including lower resistance potential and broad-spectrum activity against biofilms, but face challenges in stability and production costs. Key brands (e.g., XF-73, PL-5) target wound care and systemic infections. Market trends favor synthetic, short-chain AMPs with enhanced pharmacokinetics. Regulatory certifications (FDA, EMA) are critical for clinical adoption. Logistics require cold-chain storage due to peptide fragility. Industry growth is fueled by R&D investments and rising demand for alternatives to conventional antibiotics.